Novel Immunotherapeutics in the Pipeline

Novel Immunotherapeutics in the Pipeline is organized by Cleveland Clinic Center for Continuing Education and would be held during May 25, 2017 - May 25, 2019.

The target audience for this medical event for rheumatologists, allergists / immunologists, dermatologists, internal medicine physicians, and associated allied health practitioners, including nurse practitioners, nurses, and physician assistants interested in or using biologic therapeutics for autoimmune and inflammatory disorders. This CME Conference has been approved with a maximum of 0.50 AMA PRA Category 1 Credits.

Description :

Biologic Therapies VII: Precision Medicine in the Biologic Era online series brings together world leaders in immune-based therapies and addresses cutting-edge translational immunology and the latest data on biologic therapeutics.

This webcast will review the immunotherapeutics in development for the treatment of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), psoriatic arthritis (PsA), and spondyloarthritis (SpA) and clinical conclusions based on the studies and data currently in the pipeline.

Learning Objectives :

• Review the promising IL-6 inhibitors for treatment of RA, including mechanism of action, and potential differences in efficacy and safety profiles.
• Discuss the varied therapies in development for treatment of SLE.
• Discuss the therapies in development for treatment of PsA/Ps and IBD.

Additional details will be posted as soon as they are available.